Sort by
Keyphrases
Thrombocytopenia
84%
Lymphoma
71%
Venous Thromboembolism
64%
Novel Agents
59%
Pregnant Women
53%
Platelets
50%
Platelet Transfusion
50%
Lymphoproliferative Disorders
47%
During Pregnancy
47%
Cancer Patients
43%
In Cancer
43%
Anticoagulation
43%
Comprehensive Literature Review
35%
Multitransfused
35%
Tumor-immune System
35%
Clinical Vignette
35%
Cell Shape
35%
Vignette-based Experiment
35%
Current Treatment
35%
Fibromyalgia Patients
35%
Fibromyalgia
35%
Dendritic Cells
35%
Physically Active
35%
Religiosity
35%
Spirituality
35%
Acute Thrombocytopenia
35%
Tumor Microenvironment
35%
Immune Checkpoint Blockade
35%
T Helper
35%
Intravenous Immunoglobulin (IVIg)
35%
Erythropoietin
35%
Oncology Patients
35%
Young Female
35%
CD4+ T Helper Cells
35%
Patients with Hematological Malignancies
35%
Small Dose
35%
Atrial Fibrillation
35%
Transfusion
35%
Single-center Experience
35%
Postpartum Hemorrhage
35%
Atypical Hemolytic Uremic Syndrome (aHUS)
35%
Individual Participant Data
35%
Chimeric Antigen Receptor T Cells (CAR-T)
35%
Peripheral Blood
35%
Diffuse Large B-cell Lymphoma (DLBCL)
35%
Molecular Patterns
35%
Cellular Pattern
35%
Strenuous Exercise
31%
Therapeutic Dilemma
29%
Fetal Health
29%
Medicine and Dentistry
Platelet
100%
Thrombocytopenia
82%
Anticoagulation
62%
Venous Thromboembolism
60%
Hematologic Malignancy
53%
Antiplatelet
35%
Tumor Microenvironment
35%
Antithrombotic
35%
Cell Shape
35%
Neoplasm
35%
Immunoglobulin
35%
Lymphoproliferative Disease
35%
Immune Checkpoint Blockade
35%
Dendritic Cell
35%
T-Helper Cell
35%
Atypical Hemolytic Uremic Syndrome
35%
Lochia
35%
Chimeric Antigen Receptor T-Cell
35%
T Cell
32%
Atrial Fibrillation
29%
Antithrombotic Therapy
26%
Tumor Cell
23%
RNA Sequence
20%
Diagnosis
17%
Malignant Neoplasm
17%
Clinical Trial
17%
Physical Activity
17%
Monoclonal Antibody
17%
Plasma Exchange
17%
Chimeric Antigen Receptor T-Cell Immunotherapy
17%
Patient Selection
17%
B Cell
17%
Thrombosis
14%
Hazard Ratio
13%
T Cell Subset
11%
Non Small Cell Lung Cancer
11%
Lymph Node
11%
Specific Tumor
11%
Health Care Cost
11%
Immunotherapy
11%
Cell Interaction
11%
Myeloid Cell
11%
Blood Transfusion
11%
Antigen Presenting Cell
11%
T Cell Receptor
11%
Tumor Antigen
11%
In Vitro
11%
Ovalbumin
11%
Antigen Specificity
8%
Idiopathic Thrombocytopenic Purpura
8%
